Ilyang Pharmaceutical Discloses Corporate Governance Report: Only 7 of 15 Core Indicators Compliant (46.7%), Highlighting Need for Governance Improvement and Enhanced Shareholder Protection
Ilyang Pharmaceutical disclosed its corporate governance report as of May 29, 2026, complying with only 7 out of 15 core indicators (46.7%), indicating need for improvement.
Shareholder meeting convocation was announced only 2 weeks prior instead of 4 weeks, and electronic voting and dividend predictability were insufficient.
Board consists of 4 inside and 3 outside directors, all male, lacking gender diversity.
Audit committee is composed entirely of outside directors (including an accounting expert) ensuring independence, but failed to hold quarterly meetings with external auditors without management.
For shareholder return, the company repurchased 1 billion won worth of treasury shares in 2025 and disclosed a value-up plan in 2026.
CEO Jeongsuk Jung was recommended for dismissal by the Securities and Futures Commission for accounting standard violations, but remains in office due to a court suspension of the decision.
[AI Summary]Ilyang's corporate governance report shows a low 46.7% compliance rate, indicating urgent need for improvement, notably lacking formal dividend policy and CEO succession plan, which weakens shareholder protection. Short-term stock impact is limited, but governance enhancements are essential for long-term value creation.